RxDoctor Payments Data

Ricardo Fontanet, MD

Orthopaedic Surgery · San Juan, PRNPI 1528299054

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (55.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Smith+Nephew accounts for 92.5% of it on its own, with 6 other manufacturers making up the rest.

$6,616in general payments, 2019–2025

Across 16 payments — averaging $413.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$6K
  • Stryker$150
  • Merck$105
  • Zimmer Biomet$105
  • Johnson And Johnson International$86
  • GSK$33
  • plus $17 from 1 others

What the payments were for

  • Consulting fees$2,46037%
  • Speaking & faculty fees$3,66055%
  • Travel & lodging$621%
  • Food & beverage$4347%

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew4$6,120
Stryker2$150
Merck3$105
Zimmer Biomet4$105
Johnson And Johnson International1$86
GSK1$33
PBG Puerto Rico LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,616 in reported general payments places this provider in the 70th percentile of 94 orthopaedic surgery providers in Puerto Rico.

See all orthopaedic surgery providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$32,671
Medicare patients
47
Services billed
234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban30$16,951
Diclofenac Potassium260$9,831
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav339$7,093
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen298$4,610
Celecoxib141$3,123
Mupirocin260$2,182
Enoxaparin Sodium21$1,978
Gabapentin238$1,609
Omeprazole226$1,449
Tramadol Hcl-AcetaminophenTramadol Hcl/Acetaminophen101$1,065
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim68$351
Tramadol Hcl48$195
Methylprednisolone15$134
Cyclobenzaprine Hcl11$74

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →